![](/img/cover-not-exists.png)
34 The TGF-beta2 antisense ollgonucleotide ap 12009 as a therapeutic agent in recurrent high-grade glloma: safety and efficacy results of phase I/II clinical trials
P. Hau, U. Bogdahn, J. Schlaier, M. Mehdorn, G. Wurm, J. Pichier, M. Kunst, M. Goldbrunner, K.H. Schlingensiepen, G. StauderVolume:
1
Year:
2003
Language:
english
DOI:
10.1016/s1359-6349(03)90068-1
File:
PDF, 169 KB
english, 2003